How Did These Data Get Here? Recommendations for the Analysis of Data From ClinicalTrials.gov

Abstract

A paper by Drs Okada and Sengoku that appears in this issue of TIRS shows how data from Clinicaltrials.gov can be used for research on the pharmaceutical industry. This commentary identifies several challenges associated with using these data for research and concludes with 3 recommendations from a statistical perspective.

Keywords

Clinicaltrials.gov observational research

Get full access to this article

View all access options for this article.

References

Okada

Sengoku

. Entry into new therapeutic areas: the effect of strategic alliance on clinical trials. TIRS 2018;

Background. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/about-site/background. Accessed July 3, 2018.

History, policies, and laws. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/about-site/history. Accessed July 3, 2018.

ClinicalTrials.gov . https://clinicaltrials.gov/ct2/home. Accessed July 3, 2018.

Tse

Fain

Zarin

. How to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider. BMJ. 2018;361:k1452. doi:https://doi.org/10.1136/bmj.k1452.